0 0 0
Dieser Online-Shop verwendet Cookies für ein optimales Einkaufserlebnis. Dabei werden beispielsweise die Session-Informationen oder die Spracheinstellung auf Ihrem Rechner gespeichert. Ohne Cookies ist der Funktionsumfang des Online-Shops eingeschränkt. Sind Sie damit nicht einverstanden, klicken Sie bitte hier.

Malouf, Tannier Rare Kidney Tumors

Comprehensive Multidisciplinary Management and Emerging Therapies

ISBN: 978-3-319-96988-6

Erscheinungsdatum: Oktober 2018

Einband: Hardcover

Seitenzahl: 144 ill.

Illustrationen: 11 ill.

Verlag: Springer

Lieferzeit ab Ihrer Bestellung: 2-14 Tage je nach Lieferbarkeit und Verlag

Beschreibung

  • Aids in treatment decision-making
  • Considers a range of rare kidney tumors, including pediatric renal cell carcinomas and Wilms tumors
  • Explains the multidisciplinary management of each tumor subtype
  • Written by international experts in fields including urology, medical oncology, and pathology

This book provides clinicians with clear guidance on treatment decision-making in patients with rare kidney cancers. After a brief review on epidemiology, pathology, and biology, each chapter focuses on the multidisciplinary management of a particular tumor subtype using the full range of available cancer therapy modalities, including surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy. Emerging therapies and future directions in the management of each cancer subtype are also discussed. The chapters are all written by multidisciplinary teams of international experts comprising at least a urologist, a medical oncologist, and a pathologist.

Rare kidney cancers represent 15% of renal cell carcinomas. In comparison with clear cell renal cell carcinomas, little is known about the biology of such cancers, and few trials have reported on the efficacy of targeted therapies in the metastatic setting. Optimal management thus poses significant challenges and often requires a multidisciplinary team. This book will be an ideal reference guide for all clinicians involved in the care of patients with these orphan tumors.